Ryeqo
Generic: relugolix 40 mg, estradiol 1.0 mg, norethisterone acetate 0.5 mg
Manufacturer: Myovant Sciences · Program: Myovant Sciences Patient Assistance Program
Apply for AssistanceEligibility Criteria
Insurance Requirement
Uninsured or underinsured patients; separate copay program for commercially insured (not Medicare/Medicaid)
Residency
US resident
For uninsured or underinsured patients experiencing financial hardship; contact for eligibility
Program Information
Processing Time
2–4 weeks
Delivery Method
shipped to patient or physician office
Application Method
Phone
Reauthorization
Required — annual
Typically Required Documents
ProvisionRX prepares and organizes all required documentation as part of your enrollment management. This list is provided for informational purposes.
- proof of income
- proof of residency
- prescription
- insurance status
Indicated For
uterine fibroids, endometriosis
About This Medication
# Myovant Sciences Patient Assistance Program Patient Guide: How to Get Ryeqo at Low or No Cost Ryeqo (relugolix 40 mg, estradiol 1.0 mg, norethisterone acetate 0.5 mg) is a prescription medication used to treat certain conditions in women, and the **Myovant Sciences Patient Assistance Program** helps eligible uninsured or underinsured patients get it at no cost if they face financial hardship. ## About Ryeqo Ryeqo combines **relugolix**, a gonadotropin-releasing hormone (GnRH) receptor antagonist, with **estradiol** (a form of estrogen) and **norethisterone acetate** (a progestin). This once-daily oral tablet is prescribed for women to manage heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain related to endometriosis. It works by lowering certain hormone levels to reduce symptoms, but it should only be used under a doctor's supervision due to potential side effects like bone density loss, hot flashes, or mood changes. Always discuss risks and benefits with your healthcare provider. ## Who Qualifies for the Program? The program targets **uninsured or underinsured patients experiencing financial hardship**. While specific income thresholds (like Federal Poverty Level percentages) are not publicly detailed, eligibility focuses on those who cannot afford Ryeqo despite income efforts. U.S. residents (including territories) prescribed Ryeqo for an FDA-approved use qualify if they meet criteria assessed by Myovant Sciences. Government-insured patients (e.g., Medicare, Medicaid) may receive free product for the full coverage year if eligible, with Myovant notifying their plans. ## Income Eligibility Breakdown Exact income limits aren't fixed publicly; eligibility is determined case-by-case via phone inquiry. Contact the program for a personalized review. Here's a general overview based on similar programs: | Household Size | Typical Threshold Example (e.g., 400-500% FPL)* | Notes | |---------------|------------------------------------------------|-------| | Individual | Up to ~$60,000-$75,000 annually | Varies; proof required | | Couple | Up to ~$80,000-$100,000 annually | Household income counted | | Family of 3 | Up to ~$100,000-$125,000 annually | Includes dependents | | Family of 4 | Up to ~$120,000-$150,000 annually | Contact for exacts | *Estimates for illustration; **call (833) 674-6899** for current thresholds, as they adjust yearly and depend on hardship proof. No substitutes like assets are typically considered unless specified. ## Insurance Requirements - **Uninsured patients**: Primary targets; provide Ryeqo free if eligible. - **Underinsured**: Those with coverage gaps or high costs qualify. - **Commercially insured**: Separate copay program available (not for Medicare/Medicaid); pay as low as $10/month up to limits. - **Medicare/Medicaid**: Government plans notified if enrolled; free product possible for the year. Proof of insurance status (or lack thereof) is required. The program isn't health insurance and doesn't count toward deductibles. ## Step-by-Step Application Process 1. **Get Prescribed**: Obtain a valid Ryeqo prescription from your doctor. 2. **Gather Documents**: Prepare **proof of income** (tax returns, pay stubs, W-2s), **proof of residency** (utility bill, lease), **prescription**, and **insurance details** (cards or denial letter). 3. **Call the Program**: Dial **(833) 674-6899** (Mon-Fri, 8 AM-8 PM ET). Application is by **phone only**—no online form. 4. **Submit Info**: Provide details verbally; fax or mail documents if requested (fax: check during call). 5. **Eligibility Review**: Myovant assesses hardship; expect questions on finances. 6. **Approval Notification**: If approved, medication ships free. The process is patient-friendly—staff guide you. Enroll in the broader support program for nurse help, education, and reimbursement aid. ## Timeline and Delivery Processing time varies (typically 1-2 weeks, but call for updates). Once approved, Ryeqo ships **directly to your home or doctor's office** at no cost. **Reauthorization is required** annually or per cycle—resubmit income/proof before refill to continue. Bridge programs offer short-term free supply during delays. ## Alternatives if Denied - **Appeal**: Request review with more hardship proof. - **Copay Program**: For commercial insurance (call same number). - **Other Resources**: Check NeedyMeds.org, RxAssist.org, or RxHope.com for databases. Generic/biosimilar options: **None currently available**. - **Manufacturer Bridge**: Temporary free supply for coverage issues. - **State Programs**: Local Medicaid or charity clinics. ## Disclaimer This guide is for informational purposes only and not a guarantee of eligibility or coverage. Program terms can change; Myovant may amend/discontinue anytime. Not health insurance—doesn't apply to deductibles. Consult your doctor for medical advice. Eligibility per Myovant's sole discretion. Data based on available info as of 2026; verify by calling **(833) 674-6899**. Word count: 942.
Program information last verified: March 30, 2026
Ready to apply for Ryeqo assistance?
ProvisionRX manages the complete application process. Start your application in about 15 minutes.